Onego Bio is a company.
Onego Bio has raised $41.0M across 2 funding rounds.
Key people at Onego Bio.
Onego Bio has raised $41.0M in total across 2 funding rounds.
Key people at Onego Bio.
Onego Bio has raised $41.0M in total across 2 funding rounds.
Onego Bio's investors include Maki.vc.
# High-Level Overview
Onego Bio is a Finnish food-biotech company producing Bioalbumen®, a non-animal egg protein created through precision fermentation.[1][2] The company addresses a critical sustainability challenge in global food production by offering a bioidentical alternative to traditional chicken eggs that eliminates environmental, ethical, and safety concerns while maintaining full functional equivalence.
The company serves food manufacturers as an ingredient supplier, targeting the massive industrial egg market—particularly in the U.S., where manufacturers consume approximately one-third of all eggs produced globally.[2] Onego Bio's growth momentum is substantial: the company closed a Series A funding round securing over $40 million in capital in summer 2024[2] and has announced plans to establish a flagship manufacturing facility in Jefferson County, Wisconsin.[5] The company has also filed a GRAS (Generally Recognized as Safe) notice with the FDA to commercialize Bioalbumen® in the United States.[5]
# Origin Story
Onego Bio emerged from groundbreaking research at VTT Technical Research Centre of Finland. In 2016, co-founder Christopher Landowski, a cell agriculture trailblazer who had relocated to Finland from the U.S., began studying *Trichoderma reesei*, a fungus that could be programmed to produce egg protein entirely without animals.[2] This discovery represented a fundamental breakthrough in precision fermentation technology.
The company officially spun out of VTT in 2022 to commercialize this breakthrough.[2] Co-founder Maija Itkonen, an industrial designer and three-time founder with deep experience in food tech, joined Landowski to transform the scientific discovery into a viable business.[2] This combination of scientific expertise and entrepreneurial acumen proved pivotal. The company quickly gained international recognition, winning Fast Company's 2023 World Changing Ideas Award,[1] validating both the technology and its market potential.
# Core Differentiators
# Role in the Broader Tech Landscape
Onego Bio operates at the intersection of two powerful trends reshaping global food systems: the alternative protein movement and precision fermentation technology. The company is riding the wave of accelerating demand for sustainable protein solutions as traditional animal agriculture faces mounting pressure from climate concerns, resource scarcity, and supply chain fragility.
The timing is particularly favorable. Global protein demand continues rising, yet conventional production methods are increasingly unsustainable.[2] Precision fermentation has matured from laboratory curiosity to industrial viability, with companies like Onego Bio demonstrating that complex proteins can be produced at scale with superior environmental profiles. The company's U.S. expansion—opening San Diego headquarters in 2024 and planning Wisconsin manufacturing—signals that the technology is transitioning from European research to American commercial deployment.
Onego Bio influences the broader ecosystem by validating precision fermentation as a viable pathway for ingredient replacement at industrial scale. Unlike consumer-facing alternative protein companies, Onego Bio's B2B model targets food manufacturers directly, embedding sustainable proteins into existing supply chains rather than requiring consumer behavior change. This approach has broader systemic impact.
# Quick Take & Future Outlook
Onego Bio is positioned to become a critical infrastructure company in the alternative protein ecosystem. The company's next phase centers on manufacturing scale-up and regulatory approval in the U.S. market—the world's largest egg-consuming region. Success in these areas would validate precision fermentation as a commercially viable technology and likely accelerate adoption across other protein categories.
The company's trajectory suggests several key developments ahead: FDA approval of Bioalbumen® will unlock U.S. market entry; the Wisconsin facility will demonstrate manufacturing scalability; and successful partnerships with major food manufacturers will establish market traction. The broader question is whether Onego Bio can achieve cost parity with conventional eggs while maintaining sustainability advantages—the inflection point that determines whether precision fermentation becomes a niche solution or a fundamental restructuring of protein production.
Onego Bio has raised $41.0M across 2 funding rounds. Most recently, it raised $30.0M Series A in April 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2024 | $30.0M Series A | Maki.vc | |
| Feb 1, 2022 | $11.0M Seed | Maki.vc |
